All In Biotech

Free tool

FAERS Monitor: Arcalyst

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125249 or its brand name (Arcalyst, Rilonacept). Reports on generic versions are filed under their own applications.

Reports

1,157

Serious

284

25% of reports

Hospitalization

134

Death reported

26

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site erythema134
  • chest pain120
  • product dose omission issue103
  • pericarditis90
  • fatigue89
  • injection site pain88
  • off label use85
  • drug ineffective76
  • pain76
  • injection site pruritus68
  • injection site rash67
  • dyspnoea63
  • injection site reaction59
  • arthralgia57
  • chest discomfort50

Reports by year received

View as table
YearReports
20095
20101
20115
20124
201310
20143
20152
201614
20179
201821
201910
20207
202115
2022170
202373
2024190
2025399
2026219

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pericarditisSignal9097.980.28,497
injection site rashSignal6739.831.52,493
injection site erythemaSignal13419.716.82,366
injection site pruritusSignal6818.514.71,109
injection site reactionSignal5915.612.2794
chest painSignal12011.89.91,183
chest discomfortSignal508.96.8343
product dose omission issueSignal1036.45.3467
injection site painSignal885.24.3300
arthralgiaSignal572.51.950
painSignal762.21.853
fatigueSignal892.11.751
dyspnoeaSignal632.01.632
off label use851.81.429
drug ineffective761.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.